9 Meters Biopharma (NMTR) Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome May 30, 2023 09:26AM
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome May 30, 2023 09:25AM
9 Meters Biopharma (NMTR) Reports Q1, Provides Business Update May 15, 2023 05:17PM
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023 May 15, 2023 05:15PM
9 Meters Biopharma (NMTR) Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity Apr 5, 2023 08:05AM
View Older Stories

Apr 5, 2023 08:00AM 9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
Mar 28, 2023 08:02AM 9 Meters Biopharma (NMTR) Provides Business Update, Reports Q4
Mar 28, 2023 08:00AM 9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
Mar 7, 2023 08:00AM 9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
Jan 31, 2023 08:00AM 9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
Nov 29, 2022 08:00AM 9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
Nov 14, 2022 08:05AM 9 Meters Biopharma (NMTR) Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
Nov 14, 2022 08:00AM 9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
Nov 8, 2022 08:00AM 9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
Oct 24, 2022 08:03AM 9 Meters Biopharma (NMTR) Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies
Oct 24, 2022 08:00AM 9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific
Oct 18, 2022 08:00AM 9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Oct 17, 2022 08:01AM 9 Meters Biopharma (NMTR) Announces 1:20 Reverse Stock Split
Oct 17, 2022 08:00AM 9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
Sep 26, 2022 04:07PM 9 Meters Biopharma (NMTR) Reports Positive Final Results from Phase 2 VIBRANT Study
Sep 26, 2022 04:05PM 9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome
Sep 6, 2022 08:30AM 9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 1, 2022 08:00AM 9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
Aug 31, 2022 08:00AM 9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
Aug 15, 2022 07:00AM 9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
Jul 6, 2022 09:00AM 9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
Jun 30, 2022 08:04AM 9 Meters Biopharma (NMTR) Enters $70M Debt Facility to Support Phase 3 Study of Vurolenatide
Jun 30, 2022 08:00AM 9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Jun 30, 2022 07:00AM 9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
Jun 21, 2022 08:02AM 9 Meters Biopharma (NMTR) Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
Jun 21, 2022 08:00AM 9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
Jun 13, 2022 04:35PM 9 Meters Biopharma to Participate in the 2022 BIO International Convention
May 19, 2022 08:00AM 9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
May 18, 2022 08:04AM 9 Meters Biopharma (NMTR) Presents Preclinical Data
May 18, 2022 08:00AM 9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
May 16, 2022 07:00AM 9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
May 5, 2022 08:00AM 9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
Apr 20, 2022 09:02AM 9 Meters Biopharma (NMTR) and Celiac.com Collaborate to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
Apr 20, 2022 09:00AM 9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
Apr 13, 2022 07:03AM 9 Meters Biopharma (NMTR) Granted Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
Apr 13, 2022 07:00AM 9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
Mar 23, 2022 07:04AM 9 Meters Biopharma (NMTR) Reports Q4 Results, Provides Business Update
Mar 23, 2022 07:00AM 9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
Mar 21, 2022 08:00AM 9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
Mar 9, 2022 08:00AM 9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
Mar 2, 2022 08:02AM 9 Meters Biopharma (NMTR) Collaborates with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
Mar 2, 2022 08:00AM 9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
Feb 28, 2022 04:16PM 9 Meters Biopharma (NMTR) Provides Clinical Update
Feb 28, 2022 04:15PM 9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
Feb 25, 2022 08:00AM 9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)
Feb 9, 2022 08:00AM 9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
Jan 24, 2022 08:03AM 9 Meters Biopharma (NMTR) Granted US Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
Jan 24, 2022 08:00AM 9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
Jan 18, 2022 08:07AM 9 Meters Biopharma (NMTR) Appoints Bethany Sensenig as CFO
Jan 18, 2022 08:00AM 9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
View Older Stories